5
Clinical Trials associated with Tetravalent influenza split virion vaccine, inactivated (Hualan Biological)四价流感病毒裂解疫苗在更大规模人群的安全有效性Ⅳ期临床研究
[Translation] Phase IV clinical study on the safety and efficacy of quadrivalent influenza virus split vaccine in a larger population
评价四价流感病毒裂解疫苗在 18~59 岁健康人群中接种后的批间一致性。 评价四价流感病毒裂解疫苗在 3 岁及以上扩大人群接种后安全性和免疫原性,以期观察到 1‰的罕见不良反应。
[Translation] To evaluate the batch-to-batch consistency of quadrivalent influenza virus split vaccine after vaccination in healthy people aged 18 to 59 years. To evaluate the safety and immunogenicity of quadrivalent influenza virus split vaccine after vaccination in an expanded population of 3 years and above, in order to observe rare adverse reactions of 1‰.
Phase IV Clinical Study on Safety and Efficacy of Quadrivalent Influenza Virus Split Vaccine in Larger Population
To evaluate the inter-batch consistency (CI) of quadrivalent influenza vaccine (split virion) among healthy people aged 18-59 years; Secondly, to evaluate the safety and immunogenicity of quadrivalent influenza vaccine (split virion) in the expanded population aged 3 years and above, in order to observe the rare adverse reaction of 1‰.
[Translation] Phase IV clinical trial plan for quadrivalent influenza virus split vaccine
评价四价流感病毒裂解疫苗在3-8岁健康人群中全程2剂程序接种后的免疫原性和安全性。
[Translation] To evaluate the immunogenicity and safety of quadrivalent influenza virus split vaccine after a full 2-dose schedule in healthy people aged 3-8 years.
100 Clinical Results associated with Tetravalent influenza split virion vaccine, inactivated (Hualan Biological)
100 Translational Medicine associated with Tetravalent influenza split virion vaccine, inactivated (Hualan Biological)
100 Patents (Medical) associated with Tetravalent influenza split virion vaccine, inactivated (Hualan Biological)
100 Deals associated with Tetravalent influenza split virion vaccine, inactivated (Hualan Biological)